biocryst, Author at Biocryst

Final results from ALPHA-STAR, a Phase 1b/2 Trial of Navenibart in Hereditary Angioedema

View Article

biocryst

February 18, 2026

Hereditary Angioedema (HAE)
Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world

View Article

biocryst

February 5, 2026

Hereditary Angioedema (HAE)
Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults

View Article

biocryst

February 5, 2026

Hereditary Angioedema (HAE)
STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema

View Article

biocryst

February 5, 2026

Hereditary Angioedema (HAE)
Adherence and persistence among patients with hereditary angioedema receiving long-term prophylaxis in the United States

View Article

biocryst

January 9, 2026

Hereditary Angioedema (HAE)
Berotralstat effectiveness and safety in patients with hereditary angioedema with normal C1 inhibitor

View Article

biocryst

November 24, 2025

Hereditary Angioedema (HAE)
Reductions in medical visits and hospitalizations following berotralstat initiation in patients with hereditary angioedema in the United States

View Article

biocryst

November 24, 2025

Hereditary Angioedema (HAE)
Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: A subset analysis of the APeX-S trial

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
The Multifactorial Impact of Receiving a Hereditary Angioedema Diagnosis

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)